United States Androgens and Anabolic Steroids Market Insight
Published: 04 June 2026 | Report Format: Electronic (PDF)
United States Androgens and Anabolic Steroids Market is projected to grow at a CAGR of around 5.9%, driven by increasing prevalence of hormonal disorders, rising demand for testosterone replacement therapies, expanding geriatric population, growing awareness of men's health, and ongoing pharmaceutical advancements.
United States Androgens and Anabolic Steroids Market Forecasts to 2035
- The United States Androgens and Anabolic Steroids Market Size Was Estimated at USD 2.4 Billion in 2025.
- The Market Size is Expected to Grow at a CAGR of around 5.9% from 2025 to 2035.
- The United States Androgens and Anabolic Steroids Market Size is Expected to Reach around USD 4.3 Billion by 2035.
Notable Insights for the United States Androgens and Anabolic Steroids Market
- Segmentation Based on Product Type, Testosterone, Methyltestosterone, Nandrolone, and Oxandrolone segments held the dominant position in 2025 with nearly 76% share, driven by rising hormone replacement therapy adoption and increasing treatment of hypogonadism.
- Segmentation Based on Application, Hypogonadism, Delayed Puberty, Muscle-Wasting Disorders, and Osteoporosis segments collectively accounted for approximately 81% share in 2025, supported by growing prevalence of hormonal deficiencies and expanding therapeutic use of anabolic steroids.
- The United States Androgens and Anabolic Steroids Market is driven by AbbVie Inc., Pfizer Inc., and Endo International plc, with combined revenues of nearly USD 74.6 billion in 2025. The market is expected to grow at a CAGR of 5.9%.
Download the eBook (ToC)
- Rising prevalence of hypogonadism, increasing adoption of testosterone replacement therapies, and growing awareness of hormonal health are expected to drive market expansion, with treatment adherence improving by nearly 22% and patient outcomes by approximately 18%.
Why Buy This Report
- Provides a comprehensive analysis of the impact of hormonal disorder prevalence, testosterone replacement therapy adoption, healthcare spending trends, regulatory policies, and pharmaceutical innovations on market development.
- Offers key insights into advancements in androgen formulations, drug delivery technologies, testosterone therapies, anabolic steroid treatments, and next-generation hormonal therapeutics supporting improved patient outcomes.
- Helps market participants evaluate competitive benchmarking, investment opportunities, product development pipelines, regulatory landscapes, distribution networks, and growth strategies of leading androgen and anabolic steroid manufacturers.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United States androgens and anabolic steroids market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United States Androgens and Anabolic Steroids Market
- AbbVie Inc.
- Pfizer Inc.
- Endo International plc
- Viatris Inc.
- Teva Pharmaceutical Industries Ltd.
- Amneal Pharmaceuticals, Inc.
- Upsher-Smith Laboratories, LLC
- Sun Pharmaceutical Industries Ltd.
- Hikma Pharmaceuticals
- PLCMarius Pharmaceuticals, Inc.
Recent Developments:
- In October 2025, AbbVie Inc. announced the expansion of its testosterone replacement therapy portfolio in the United States, introducing enhanced hormone management solutions focused on improving treatment adherence, patient convenience, and long-term therapeutic outcomes.
- In July 2025, Pfizer Inc. entered a strategic collaboration with Marius Pharmaceuticals, Inc. to support the development of next-generation androgen therapies, focusing on innovative drug delivery technologies, improved efficacy profiles, and expanded treatment options for hormone deficiency disorders.
Market Segmentation:
United States Androgens and Anabolic Steroids Market, By Product Type
• Testosterone
• Methyltestosterone
• Nandrolone
• Oxandrolone
• Other Androgen & Anabolic Steroid Products
United States Androgens and Anabolic Steroids Market, By Route of Administration
• Injectable
• Oral
• Transdermal Gels & Creams
• Patches
• Implantable Pellets
United States Androgens and Anabolic Steroids Market, By Application
• Hypogonadism
• Delayed Puberty
• Muscle-Wasting Disorders
• Osteoporosis
• Hormone Replacement Therapy (HRT)
United States Androgens and Anabolic Steroids Market, By End User
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Homecare Settings
• Research & Academic Institutes
United States Androgens and Anabolic Steroids Market, By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Specialty Pharmacies
• Drug Distribution Networks
Expert Views:
The United States Androgens and Anabolic Steroids Market is poised for steady growth through 2035, supported by rising prevalence of hormonal disorders, increasing adoption of testosterone replacement therapies, and continuous pharmaceutical innovation. Growing awareness of men’s health, expanding therapeutic applications, and advancements in drug delivery technologies are expected to strengthen market demand, while leading manufacturers focus on portfolio expansion and strategic collaborations to enhance their competitive positioning.
Author: Sanket and Pranali By Spherical Insights and Consulting